Company intelligence / Profile preview
Cytovant
China
- Ownership
- Private
- Development stage
- Other
01
Overview
Cytovant is developing TCR-T cell and dendritic cell (DC) therapies, with a focus on targets NY-ESO-1, WT-1, and PRAME, specifically tailored for patient populations in East Asia. These programs, licensed from Medigene and developed in collaboration, are in preclinical or early clinical stages; no late stage or pivotal clinical results have been reported yet.
- Therapeutic areas
- Oncology
- Modalities
- T cell receptor engineered T cell therapyDendritic cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MedigeneSinovant Sciences
Beyond the preview
Go deeper on Cytovant.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytovant.